Standard of care

MindMed Reports 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Senior, Week, ODT, MindMed, FDA, University Hospital of Basel, DSM-IV codes, Standard of care, GAD, Patient, Anxiety, Medicine, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.
  • “2023 was a highly productive year for MindMed, which concluded with positive Phase 2b results for MM120 in the treatment of adult patients with GAD,” said Rob Barrow, Chief Executive Officer and Director of the Company.
  • As of December 31, 2023, MindMed had cash and cash equivalents totaling $99.7 million compared to $142.1 million as of December 31, 2022.
  • MindMed management will host a conference call at 8:00 AM EST today to provide a corporate update and review the Company’s 2023 financial results.

Infusion Nurses Society Adds Vascular Access Safety Devices Such as the Orchid SRV to Standard of Care Guidelines

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Nursing, Managed Care, General Health, Health, Medical Devices, Hospitals, Health Technology, Hospital, BSN, Therapy, Doctor of Philosophy, RN, Orchid, Intravenous therapy, INS, Delirium, Confusion, Standard of care, Risk, Outline of health sciences, Safety, VADS, Deficit spending, Gold, Patient, Dementia, Veterans' affairs, Medical device

Linear Health Sciences , a medical device company that has developed a proprietary, breakaway safety valve platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to encompass devices designed to reduce the risk of vascular access device (VAD) dislodgement, including the Orchid SRV tension-activated breakaway safety release valve.

Key Points: 
  • Linear Health Sciences , a medical device company that has developed a proprietary, breakaway safety valve platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to encompass devices designed to reduce the risk of vascular access device (VAD) dislodgement, including the Orchid SRV tension-activated breakaway safety release valve.
  • The guidelines also flag pediatric patients and those with cognitive issues such as delirium or dementia as being at increased risk for IV dislodgement.
  • The Orchid SRV is a sterile, single-use connector for needle-free access that makes return to treatment fast, simple, and clean, and improves both the patient and clinician experience.
  • Clinical simulation testing of 360 Orchid SRVs showed that the device prevented IV dislodgement by 91.9 percent across all test groups.

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Therapy, Regeneration, EVP, Multimedia, MD, Neuropathic pain, Physician, FDA, Standard of care, Orthopedic surgery, MHQ, Safety, Associate, Nerve, Patient, Sympathetic nervous system, Lead author

At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.

Key Points: 
  • At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care.
  • The secondary endpoints, including the Numerical Pain Rating Scale, also showed statistically significant improvements, favoring NTX-001 at the 24-week timepoint.
  • Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products and therapeutics to repair and regenerate peripheral nerves.
  • Neuraptive Therapeutics, Inc. disclaims any obligation to update the information contained in these forward-looking statements.

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Medical Devices, Health, Health Technology, Pharmaceutical, Optical, Biotechnology, Investment, Standard of care, Conference, IPR, GAAP, Webcast, Patent, Patient, FY, Retina, EPS, Corporation, GKOS, Glaucoma

Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.

Key Points: 
  • Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.
  • Non-GAAP SG&A expenses for the fourth quarter of 2023 increased 22% to $62.3 million, compared to $51.1 million in the same period in 2022.
  • Loss from operations in the fourth quarter of 2023 was $38.6 million, compared to operating loss of $33.7 million in the fourth quarter of 2022.
  • Non-GAAP loss from operations in the fourth quarter of 2023 was $32.4 million, compared to non-GAAP operating loss of $27.4 million in the fourth quarter of 2022.

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Cardiology, Biotechnology, Volume overload, Pacyna, Diuretic, Physician, Acute decompensated heart failure, Leg, Standard of care, Heart failure, ADHF, FASTR, Reprieve, Fatigue, Patient, Medtronic, Circulatory system, Pharmaceutical industry

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

Heart Failure Monitoring Technology Doubles Sensitivity for Predicting Events While Minimizing False Alerts Versus Standard of Care

Retrieved on: 
Wednesday, March 6, 2024
SAN, Algorithm, Peter Hancock (professor), MD, FDA, MHS, Hospital, Standard of care, Duke University Hospital, Heart failure, Biomarker, Patient, THT, Observational study, Research, Pharmaceutical industry

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

Key Points: 
  • SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
  • It demonstrated this using the same monitoring routine patients already follow in weighing themselves daily and concurrently minimized false alerts for care teams, generating nearly 40 percent fewer overall alerts.
  • Over the course of the study, the Congestion Index correctly predicted 48 of 69 heart failure events (70%), demonstrating significantly higher sensitivity (p
  • In addition to demonstrating greater sensitivity in detecting heart failure events, the Congestion Index did so with a lower alert rate, generating only 2.58 alerts per patient-year compared to the 4.18 produced by the standard of care.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

National Alliance of Healthcare Purchaser Coalitions Releases Employer Recommendations to Address Obesity Coverage

Retrieved on: 
Tuesday, February 27, 2024
Bias, Sustainability, Physician, Obesity, Cardiovascular disease, Cancer, Standard of care, Health, Council, Organization, Type, Disease, Conditional sentence, Science, Workforce, National Alliance, Fast food

WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Obesity affects more than 40% of the US population with far-reaching consequences for not only individuals but employers grappling with the negative impact to workforce health. With the recent introduction of innovative new therapies to treat obesity, the standard of care is rapidly evolving. To help employers and other purchasers make informed coverage decisions about comprehensive, holistic approaches to obesity care, the nonprofit National Alliance of Healthcare Purchaser Coalitions (National Alliance) released guidance today from its National Obesity Advisory Council made up of employers, business coalitions, and medical experts.

Key Points: 
  • To help employers and other purchasers make informed coverage decisions about comprehensive, holistic approaches to obesity care, the nonprofit National Alliance of Healthcare Purchaser Coalitions (National Alliance) released guidance today from its National Obesity Advisory Council made up of employers, business coalitions, and medical experts.
  • The coverage guidance and full report, Addressing Obesity through Holistic Design for Affordability and Sustainability, can be downloaded here .
  • "As the science of obesity evolves, employers will have better resources and tools to address the needs of their employees," said Margaret Rehayem, National Alliance vice president.
  • The National Obesity Advisory Council is an experienced group of leaders from National Alliance member coalitions, clinicians and other industry experts deeply involved in assessing and making recommendations about obesity coverage and treatment best practices.

Carbon and Desktop Health Join Forces in Consortium with Diverse and Trusted Pillars of the Oral Health Industry to Advance the Adoption of Innovative Digital Dentistry Applications

Retrieved on: 
Thursday, February 22, 2024
Diamond, FDA, Senior, Dentistry, Health, Standard of care, Patient, Partnership

REDWOOD CITY, Calif., Feb. 22, 2024 /PRNewswire/ -- Carbon, a leading product development and manufacturing technology company, today announced that it is partnering with Heartland Dental, Desktop Health™, an industry-leading dental technology innovator, and Dr. Robert Mongrain. The consortium's goal is to unite their perspectives to focus on enhancing patient outcomes by creating streamlined workflows for digitally designed removable denture appliances.

Key Points: 
  • The consortium's goal is to unite their perspectives to focus on enhancing patient outcomes by creating streamlined workflows for digitally designed removable denture appliances.
  • The dental industry is undergoing a historic and exciting digital transformation as it leads industries of all types into the digital era.
  • Technological advancements, particularly in the additive manufacturing space, are enabling more efficient and predictable dental restorations for greater patient outcomes and care.
  • Collaboration like this within the dental community can more effectively leverage industry-leading innovations for the highest standard of patient care.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024
NOK, CFO, Cevira, Traction, Physician, BLC, Growth, APM, Citizenship, Bladder cancer, Standard of care, Cystoscopy, Patient, Congress, Cropping system, Bank statement, Pharmaceutical industry

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.